| Latest Abbott Laboratories News Headlines |
| Date | Time | Source | |
| 07/16/2008 | 7:34AM | PRNUS | Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter and Raises Full-Year Outlook
- Worldwide Sales Increased 14.8 Percent -
ABBOTT PARK, Ill., July 16 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2008.
* Diluted earnings per share, excluding specified items, were $0.84,
above Abbott's previously announced guidance... More...>> |
| 07/07/2008 | 9:31AM | PRNUS | Seven Summits Research Releases Comments on AA, ABT, STZ, SGR and PBG
CHICAGO, July 7 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide.
The Seven Summits Strategic Investments Stocks To Watch Guide (go to:
http://www.iotogo.com/StocksToWatch) provides investors with essential information on stocks that may be poised for a significant move. By featuring... More...>> |
| 06/30/2008 | 8:57AM | PRNUS | Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 30 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) will announce its 2008 second-quarter financial results on Wednesday, July 16, 2008, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be... More...>> |
| 06/27/2008 | 9:33AM | PRNUS | Earvin 'Magic' Johnson and Abbott Bring 'I Stand with Magic' Program: Part of the Campaign to End Black HIV/AIDS to Facebook Com
ABBOTT PARK, Ill., June 27 /PRNewswire-FirstCall/ -- Summary
-- In conjunction with National HIV Testing Day, the Magic Johnson Foundation, http://www.magicjohnson.org/ and Abbott (NYSE:ABT), http://www.abbott.com/, launched a new Facebook group to further engage young adults in the "I Stand With Magic", http://istandwithmagic.com/... More...>> |
| 06/13/2008 | 2:00AM | PRNUS | Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
PARIS, June 13 /PRNewswire-FirstCall/ -- Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years... More...>> |
| 06/13/2008 | 2:00AM | PRNUS | HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings Fr
Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe
PARIS, June 13 /PRNewswire-FirstCall/ -- New data announced today showed that treating patients with early, active rheumatoid arthritis (RA) with Abbott's HUMIRA(R) (adalimumab) and methotrexate (MTX) resulted in an indirect cost savings of euro... More...>> |
| 06/12/2008 | 2:03PM | PRNUS | Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster
Company Invests $53 Million in New Lake County, Illinois, Pharmaceutical Development Center
ABBOTT PARK, Ill., June 12 /PRNewswire-FirstCall/ -- Today Abbott (NYSE:ABT) officially opens its new Formulation Development Center at the company's headquarters in Abbott Park, Ill. The new facility provides leading capabilities... More...>> |
| 06/09/2008 | 1:00PM | PRNUS | Now Playing: Spike Lee Stands with Earvin 'Magic' Johnson, Cookie Johnson and Abbott to Launch National PSA Campaign
LOS ANGELES, June 9 /PRNewswire-FirstCall/ -- Today, Earvin "Magic" Johnson (http://www.magicjohnson.com/index.php?/foundation/), Cookie Johnson, Abbott (http://www.abbott.com/) (NYSE:ABT) and the Magic Johnson Foundation launched a public service announcement campaign as part of the "I Stand With Magic Program," part... More...>> |
| 06/07/2008 | 4:45PM | PRNUS | Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in P
TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- New data from a sub-group analysis of patients with mixed dyslipidemia and type 2 diabetes that were enrolled in a Phase... More...>> |
| 06/06/2008 | 10:16AM | PRNUS | Abbott Declares 338th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 6 /PRNewswire-FirstCall/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 36 cents per share.
This marks the 338th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2008, to shareholders of record... More...>> |
| 06/02/2008 | 9:46AM | PRNUS | Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care
Company's Report Entitled, 'Ingenuity at Work,' Discusses Abbott's Contributions to Access, Innovation, Science Education and the Environment
ABBOTT PARK, Ill., June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today released its 2007 Global Citizenship Report, "Ingenuity at Work," which is available online at http://www.abbott.com/citizenship... More...>> |
| 06/02/2008 | 9:05AM | PRNUS | Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting Stent
TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) today announced that it has submitted an application for Seizo Hanbai Shonin (Marketing Authorization License) to Japan's Ministry of Health... More...>> |
| 05/31/2008 | 12:01PM | PRNUS | Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on
Data Show TriLipix (ABT-335) in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL and Triglycerides and Had Reported Safety Consistent with Monotherapies
SEATTLE, May 31 /PRNewswire-FirstCall/ -- New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM... More...>> |
| 05/21/2008 | 12:15PM | PRNUS | Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintaine
Three of Four HUMIRA Patients from CHARM Study in Remission at One Year Maintained Remission at Two Years
ABBOTT PARK, Ill., May 21 /PRNewswire-FirstCall/ -- Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with... More...>> |
| 05/19/2008 | 8:00AM | PRNUS | ZonePerfect Dark Chocolate Nutrition Bars Indulge Chocoholics
Abbott Nutrition creates first-of-its-kind bar combining bittersweet dark chocolate taste with antioxidants and protein for delicious, balanced nutrition on-the-go
COLUMBUS, Ohio, May 19 /PRNewswire-FirstCall/ -- (NYSE:ABT) -- Abbott Nutrition today announced the launch of ZonePerfect(R) Dark Chocolate All-Natural Nutrition... More...>> |
| 05/15/2008 | 9:00PM | PRNUS | Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Studies Show ABT-263 and ABT-869 to be Promising in Targeting Cancer Cells' Underlying Mechanisms
ABBOTT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Abbott scientists will highlight the latest clinical trial data of several investigative compounds in the company's oncology pipeline at this year's American Society of... More...>> |
| 05/13/2008 | 9:30AM | PRNUS | XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Yea
Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS
BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial... More...>> |
| 05/08/2008 | 8:00AM | PRNUS | New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial
Vicodin CR (hydrocodone bitartrate and acetaminophen) Extended Release Tablets Twice-daily Regimen Significantly Lowered Chronic Low Back Pain Intensity with 12-hour Dosing Compared to Placebo
TAMPA, May 8 /PRNewswire-FirstCall/ -- New Phase III study data showed that Abbott's investigational hydrocodone bitartrate... More...>> |
| 05/07/2008 | 12:00PM | PRNUS | Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
Phase II Data Demonstrate Abbott's Most Advanced NNR Candidate ABT-089 Shows Strong Safety, Tolerability And Efficacy in Adults With ADHD
ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and other leading scientists will present new Phase II data showing that ABT-089, a selective neuronal nicotinic... More...>> |
| 05/07/2008 | 9:51AM | PRNUS | Abbott to Present at Citi Investment Research Global Health Care Conference
ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) will present at the Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 7 a.m. Central time.
A... More...>> |